STOCK TITAN
  1. Home
  2. News
  3. EQ

Equillium to Present at the BTIG Virtual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.

Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will provide a high-level overview of the Company’s clinical focus before engaging in a Fireside Chat with BTIG equity research analyst Justin Zelin.

Date:

     

Tuesday, August 10, 2021

Time:

     

12:00 PM Eastern Time | 9:00 AM Pacific Time

Location:

     

Virtual Webcast

BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Stock EQ logo
Equillium, Inc.

NASDAQ:EQ

EQ Rankings

#4678 Ranked by Market Cap
#5167 Ranked by Stock Gains
N/A Ranked by Dividends

EQ Latest News

Apr 3, 2024
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 1, 2024
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Mar 25, 2024
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Mar 22, 2024
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
Dec 21, 2023
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

EQ Stock Data

55.00M
17.76M
36.42%
21.65%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LA JOLLA

About EQ

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.